Global Antibody Drug Conjugates Market, By Product (Adcetris, Kadcyla, and Other Product Types), By Application (Blood Cancer, Breast Cancer, Ovary Cancer, and Other Applications) By End User (Hospitals and Speciality Cancer Centers, Biotechnology and Pharmaceutical Companies, and Other End Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the global Antibody Drug Conjugates Market accounted for USD 7.2 billion and is expected to grow to around USD 34.7 billion in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 17.5%.

The market is mainly driven by an increase in cancer incidences globally. ADCs are intended to deliver a cytotoxic payload directly to cancer cells while sparing healthy cells, making treatment more focused, efficient, and with fewer side effects. A monoclonal antibody, a cytotoxic substance, and a linker that joins the to make up an ADC.

A particular antigen on the surface of cancer cells is recognized and bound to by the monoclonal antibody. The cancer cell internalizes the ADC once it has been bonded, and the cytotoxic chemical is then released, leading to cell death. Because of the lack of health insurance coverage, the number of patient visits decreases in hospitals, and the COVID-19 pandemic harmed product sales. The possible approval of ADCs like Adcetris for other applications was delayed due to the lack of participants in clinical trial trials.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Market Growth: The global Antibody Drug Conjugates (ADCs) market was valued at USD 7.2 billion in 2022 and is expected to reach USD 34.7 billion by 2032, with a CAGR of 17.5% between 2023 and 2032.
• Cancer Incidences: Increasing cancer cases worldwide are a major driver of the ADC market. ADCs deliver cytotoxic payloads directly to cancer cells while sparing healthy cells, making treatment more focused and efficient.
• Application Analysis: Breast cancer treatment occupies the largest market share due to the rising approvals of ADCs for breast cancer. Blood cancer treatment is also expected to have a significant market presence.
• Technology Analysis: Cleavable linkers dominate the market due to their stability in the bloodstream and controlled cytotoxin release. This technology is expected to continue to grow.
• Product Analysis: Non-cleavable linkers, like Kadcyla for breast cancer, are on the rise. These linkers provide high stability for antigen-negative cells.
• End-User Analysis: Hospitals and specialty cancer centers are the primary end-users of ADCs. They manage patient side effects and ensure appropriate treatment.
• Market Drivers: Technological advancements, rising cancer prevalence, government support for cancer research, and expanding healthcare systems are driving market growth.
• Restraints: High production costs, side effects, and challenges in production, such as raw material costs and skilled labor, are restraining factors.
• Opportunities: Increased government involvement in cancer prevention and treatment, along with public and private sector collaborations, offers growth opportunities.
• Trends: ADCs are increasingly used in cancer treatment due to their targeted approach, and the FDA has approved several ADCs. The market is expected to revive after the COVID-19 pandemic.
• COVID-19 Impact: The pandemic led to decreased revenue due to fewer patient visits and diagnosis rates. However, post-pandemic, increased adoption of modern medical procedures is expected.
• Regional Analysis: North America dominates with a 40.0% market share, driven by rising healthcare expenses. Europe follows, with increasing cancer prevalence.
• Key Players: Major companies are focusing on growth strategies like product development, approvals, and mergers & acquisitions to enhance their market presence.

Application Analysis

The largest market share for global antibody drug conjugates derives from the breast cancer category. Breast glandular tissue is where breast cancer, a non-transmissible illness, develops. The World Health Organization (WHO) estimates that 2.3 million women will receive a breast cancer diagnosis. The expansion of this market is being driven by the increasing number of approvals for antibody-drug conjugates that can be used to treat breast cancer.

Throughout the forecast period, the blood cancer sector is anticipated to occupy a sizable proportion of the market. Blood cancer, the fifth most frequent malignancy, has a variety of different forms and affects the blood cells. Leukaemia and lymphoma have both been more common in recent years.

Technology Analysis

The cleavable linker segment dominated the market with a greater market share. Cleavable linkers are the most widely utilized technology to improve the effectiveness of ADCs in the treatment of cancer because they can stay secure in the bloodstream for a longer period and release cytotoxin from ADCs.

For instance, the Chinese National Medical Products Administration (NMPA) approved the use of Seagen & Takeda’s Adcetris in 2020 for the therapy for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). Throughout the forecast period, these factors are anticipated to propel the cleavable linker market segment.

Product Analysis

The non-cleavable linker segment is expanding due to the fast-rising Kadcyla usage. The non-cleavable linker technology-based antibody-drug conjugate used in the treatment of breast cancer is called Kadcyla. The projection term is expected to see a strong increase in the non-cleavable linker sector. High-stability non-cleavable linkers aid in the death of antigen-negative cells. The medication Adcetris, which is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma, comprises the active ingredient brentuximab vedotin. It functions by locating and eliminating cancer cells.

End-User Analysis

Based on end-user, the Hospitals, and Speciality Cancer Centers segment dominate the global antibody drug conjugates market with the largest revenue share. Patients that require specific therapy are given ADCs by hospitals and specialized cancer clinics. To achieve this, it is necessary to manage any side effects or adverse reactions, as well as to make sure that patients are given the appropriate amount of the ADC and are responding to treatment as expected.

Key Market Segments

Based on Product

• Adcetris
• Kadcyla
• Other Product Types

Based on Application

• Blood Cancer
• Breast Cancer
• Ovary Cancer
• Lung Cancer
• Skin Cancer
• Brain Tumor
• Other Applications

Based on Technology

• Cleavable Linker
• Non-cleavable Linker

Based on Target Type

• CD30 Antibodies
• HER2 Antibodies
• Other Target Types

Based on End-User

• Hospitals and Speciality Cancer Centers
• Biotechnology and Pharmaceutical Companies
• Other End Users

Drivers

Technological advancements

The first-generation ADCs’ limited success (developed in the early 2000s) paved the way for second-generation ADCs to enter the global antibody drug conjugates market (from 2010 onwards). These ADCs have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies, and more stable linkers between the drug and the antibody. Nevertheless, Third-generation ADCs (2019 and later) use site-specific conjugation techniques in place of random coupling, enabling rigorous control over payload conjugation to produce a homogenous result.

Increasing prevalence of cancer

Cancer incidence grows with age due to a rise in the risk of certain tumors as people get older. When a person gets older, cellular repair mechanisms become less efficient, which increases the danger. The demand for ADCs is being pulled down by the rising cancer incidence. According to GLOBOCAN 2020, there were around 10.0 million cancer-related deaths and 19.3 million new cases of cancer worldwide.

Restraints

High production costs

The cost of raw materials, the use of technology, the lengthy production process, and the demand for a competent and The majority of the expense of producing antibody-drug conjugates is attributed to professional labor. Moreover, changes in the cost of resources have an impact on production costs. Companies in the biotechnology and pharmaceutical industries spend a lot of money on R&D.

Side-effects

ADCs have a reasonable side-effect profile due to their high selectivity, with nausea and vomiting being the most frequent toxicities. This changes, nevertheless, according to the ADC and the supplementary payload. Other side effects include stomatitis, vomiting, infection, fever, and nausea. Low blood counts, liver damage, including infusion-related reactions (IRRs), hepatic veno-occlusive disease, and bleeding are among these significant adverse effects.

Opportunity

Increasing the contribution of the public and commercial sectors to the fight against cancer

Governments are motivated to engage in cancer preventive research initiatives in light of public health concerns and the continually increasing prevalence of cancer worldwide. Also, many governments in developing nations are concentrating on enhancing the healthcare system to provide cancer patients with efficient therapy. The support for the manufacture of antibody-drug conjugates will increase due to the government’s expanding engagement in cancer prevention; this will help the market’s expansion throughout the anticipated timeframe.

Trends

ADCs are being utilized more frequently in the treatment of cancer because they provide a targeted strategy that can increase efficacy and decrease side effects as compared to traditional chemotherapy. The FDA has approved several ADCs for the treatment of cancer, and many more are in development.

Regional Analysis

North America dominates the global antibody drug conjugates market with a market share of 40.0%. rising healthcare expenses and the introduction of new products are important drivers of the antibody-drug conjugates market in North America. Also, the anticipated timeframe will see an increased focus on the need for antibody-drug conjugates due to the expanding number of cancer patients.

Europe holds the second-largest market for antibody-drug conjugates globally. The market growth in the region is a result of the increasing prevalence of cancer in European nations, which accounts for over 25% of all fatalities in the United Kingdom each year.

Key Regions

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major companies are focusing on growth strategies such as product developments, new product approvals, and mergers & acquisitions to enhance their share of the worldwide antibody drug conjugates market. For instance, Immunomedics, Inc. was acquired by Gilead for D21.0 billion. Adcetris from Takeda has also been likened to China’s NMPA for the treatment of adult patients with ALCL or systemic Hodgkin lymphoma.

Market Key Players

• Takeda Pharmaceutical Company Limited
• Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• AstraZeneca
• Gilead Sciences, Inc.
• Astellas Pharma, Inc.
• Seagen, Inc.
• Daiichi Sankyo Company, Limited
• GlaxoSmithKline plc
• Adc Therapeutics Saa
• ImmunoGen Inc.
• Bayer AG
• Novartis AG
• Agensys Inc.
• Concortis Biotherapeutics
• NBE-Therapeutics
• Spirogen
• Oxford BioTherapeutics
• Other Key Players

Recent Developments

• In June 2022: ADC Therapeutics was in the process of introducing its medication, camidanlumab tesirine, which is the second ADC, to the company’s portfolio. Phase 2 of the clinical trial for the medication produced encouraging findings. As a potential treatment for Hodgkin’s lymphoma, they are probably going to petition for FDA approval.
• In June 2022: Spirea Limited stated that it has received GBP 2.4 million in funding from investors for the development of highly specialized ADCs for the treatment of solid tumors. Their innovation allows for a larger drug-to-antibody ratio, which increases the amount of medicine administered to the affected area to kill cancer cells. This would support the treatment of cancer in more ways.
• In May 2022: Fam-trastuzumab deruxtecan-nxki (Enhertu), which was created to treat metastatic HER2, a form of positive breast cancer, received FDA approval for usage in May 2022. Along with AstraZeneca, Daiichi Sankyo created the medication.

 Report Scope